Depolarization-induced retrograde synaptic inhibition in the mouse cerebellar cortex is mediated by 2-arachidonoylglycerol

Journal of Physiology

Volumn 577, Issue 1, 2006, Pages 263-280

  Szabo, Bela ^a   Urbanski, Michal J ^a   Bisogno, Tiziana ^b   Di Marzo, Vincenzo ^b   Mendiguren, Aitziber ^a   Baer, Wolfram U ^a   Freiman, Ilka ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b CNR   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

1,6 HEXAMETHYLENEDICARBAMIC ACID BIS(CYCLOHEXANONE OXIME) ESTER; 2 ARACHIDONOYLGLYCEROL; ACYLGLYCEROL LIPASE; ANANDAMIDE; CALCIUM; DIACYLGLYCEROL KINASE INHIBITOR; FATTY ACID AMIDASE; LIPOPROTEIN LIPASE; PHOSPHOLIPASE C INHIBITOR; PROTEIN KINASE (CALCIUM,CALMODULIN) II; TETRAHYDROLIPSTATIN; 1 DIACYLGLYCEROL LIPASE; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II; CALCIUM ION; CALMODULIN; PHOSPHOLIPASE C; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CALCIUM CELL LEVEL; CALCIUM TRANSPORT; CATALYSIS; CEREBELLUM CORTEX; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME DEGRADATION; ENZYME INHIBITION; LIPID ANALYSIS; LIPOGENESIS; MOUSE; MOUSE STRAIN; NERVE CELL MEMBRANE STEADY POTENTIAL; NERVE CELL STIMULATION; NONHUMAN; PRIORITY JOURNAL; PURKINJE CELL; RAT; SIGNAL TRANSDUCTION; SUBSTANTIA NIGRA; SYNAPTIC INHIBITION; DEPOLARIZATION INDUCED RETROGRADE SYNAPTIC INHIBITION; SUBSTANTIA NIGRA PARS RETICULATA;

ANIMALS; ARACHIDONIC ACIDS; CELLS, CULTURED; CEREBELLAR CORTEX; GLYCERIDES; INTERNEURONS; MEMBRANE POTENTIALS; MICE; NEURAL INHIBITION; NEUROTRANSMITTER AGENTS; POLYUNSATURATED ALKAMIDES; PURKINJE CELLS; SYNAPTIC TRANSMISSION;

EID: 33750711997     PISSN: 00223751     EISSN: 14697793     Source Type: Journal    
DOI: 10.1113/jphysiol.2006.119362     Document Type: Article

References (84)

1. Alger BE (2002). Retrograde signaling in the regulation of synaptic transmission: Focus on endocannabinoids. Prog Neurobiol 68, 247-286.
2. Appendino G, de Petrocellis L, Trevisani M, Minassi A, Daddario N, Moriello AS et al. (2005). Development of the first ultra-potent 'capsaicinoid'agonist at transient receptor potential vanilloid type 1 (TRPV1) channels and its therapeutic potential. J Pharmacol Exp Ther 312, 561-570.
3. Azad SC, Monory K, Marsicano G, Cravatt BF, Lutz B, Zieglgänsberger W & Rammes G (2004). Circuitry for associative plasticity in the amygdala involves endocannabinoid signaling. J Neurosci 24, 9953-9961.
4. Bisogno T, Cascio MG, Saha B, Mahadevan A, Urbani P, Minassi A et al. (2006). Development of the first potent and specific inhibitors of endocannabinoid biosynthesis. Biochim Biophys Acta 1761, 205-212.
5. Bisogno T, Howell F, Williams G, Minassi A, Cascio MG, Ligresti A et al. (2003). Cloning of the first sn1-DAG lipases points to the spatial and temporal regulation of endocannabinoid signaling in the brain. J Cell Biol 163, 463-468.
6. Bisogno T, Melck D, De Petrocellis L, Bobrov MY, Gretskaya NM, Bezuglov VV, Sitachitta N, Gerwick WH & Di Marzo V (1998). Arachidonoylsrotonin and other novel inhibitors of fatty acid amide hydrolase. Biochem Biophys Res Commun 248, 515-522.
7. Bisogno T, Melck D, De Petrocellis L & Di Marzo V (1999). Phosphatidic acid as the biosynthetic precursor of the endocannabinoid 2-arachidonoylglycerol in intact mouse neuroblastoma cells stimulated with ionomycin. J Neurochem 72, 2113-2119.
8. Brenowitz SD, Best AR & Regehr WG (2006). Sustained elevation of dendritic calcium evokes widespread endocannabinoid release and suppression of synapses onto cerebellar Purkinje cells. J Neurosci 26, 6841-6850.
9. Brenowitz SD & Regehr WG (2003). Calcium dependence of retrograde inhibition by endocannabinoids at synapses onto Purkinje cells. J Neurosci 23, 6373-6384.
10. Brenowitz SD & Regehr WG (2005). Associative short-term synaptic plasticity mediated by endocannabinoids. Neuron 45, 419-431.
11. Brown SP, Brenowitz SD & Regehr WG (2003). Brief presynaptic bursts evoke synapse-specific retrograde inhibition mediated by endogenous cannabinoids. Nat Neurosci 6, 1048-1057.
12. Brown SP, Safo PK & Regehr WG (2004). Endocannabinoids inhibit transmission at granule cell to Purkinje cell synapses by modulating three types of presynaptic calcium channels. J Neurosci 24, 5623-5631.
13. Cascio MG, Minassi A, Ligresti A, Appendino G, Burstein S & Di Marzo V (2004). A structure-activity relationship study on N-arachidonoyl-amino acids as possible endogenous inhibitors of fatty acid amide hydrolase. Biochem Biophys Res Commun 314, 192-196.
14. Chen K, Ratzliff A, Hilgenberg L, Gulyas A, Freund TF, Smith M, Dinh TP, Piomelli D, Mackie K & Soltesz I (2003). Long-term plasticity of endocannabinoid signaling induced by developmental seizures. Neuron 39, 599-611.
15. Chevaleyre V & Castillo PE (2003). Heterosynaptic LTD of hippocampal GABAergic synapses: A novel role of endocannabinoids in regulating excitability. Neuron 38, 461-472.
16. Chevaleyre V, Takahashi KA & Castillo PE (2006). Endocannabinoid-mediated synaptic plasticity in the CNS. Annu Rev Neurosci 29, 37-75.
17. Cravatt BF, Demarest K, Patricelli MP, Bracey MH, Giang DK & Martin BR (2001). Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc Natl Acad Sci U S A 98, 9371-9476.
18. Cravatt BF & Lichtman AH (2003). Fatty acid amide hydrolase: An emerging target in the endocannabinoid system. Curr Opin Chem Biol 7, 469-475.
19. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, Gibson D, Mandelbaum A, Etinger A & Mechoulam R (1992). Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258, 1946-1949.
20. Di Marzo V (2005). The biosynthesis, fate and pharmacological properties of endocannabinoids. In Cannabinoids, Handbook of Experimental Pharmacology, ed. Pertwee RG, vol. 168, pp 147-185. Springer-Verlag, Heidelberg.
21. Di Marzo V, Fontana A, Cadas H, Schinelli S, Cimino G, Schwartz J-C & Piomelli D (1994). Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature 372, 686-691.
22. Diana MA, Levenes C, Mackie K & Marty A (2002). Short-term retrograde inhibition of GABAergic synaptic currents in rat Purkinje cells is mediated by endogenous cannabinoids. J Neurosci 22, 200-208.
23. Diana MA & Marty A (2003). Characterization of depolarization-induced suppression of inhibition using paired interneuron -Purkinje cell recordings. J Neurosci 23, 5906-5918.
24. Diana MA & Marty A (2004). Endocannabinoid-mediated short-term synaptic plasticity: Depolarization-induced suppression of inhibition (DSI) and depolarization-induced suppression of excitation (DSE). Br J Pharmacol 142, 9-19.
25. Dinh TP, Carpenter D, Leslie FM, Freund TF, Katona I, Sensi SL, Kathuria S & Piomelli D (2002). Brain monoglyceride lipase participating in endocannabinoid inactivation. Proc Natl Acad Sci U S A 99, 10819-10824.
26. Edwards DA, Kim J & Alger BE (2006). Multiple mechanisms of endocannabinoid response initiation in hippocampus. J Neurophysiol 95, 67-75.
27. Engler B, Freiman I, Urbanski M & Szabo B (2006). Effects of exogenous and endogenous cannabinoids on GABAergic neurotransmission between the caudate-putamen and the globus pallidus in the mouse. J Pharmacol Exp Ther 316, 608-617.
28. Fink CC & Meyer T (2002). Molecular mechanisms of CaMKII activation in neuronal plasticity. Curr Opin Neurobiol 12, 293-299.
29. Freiman I, Anton A, Monyer H, Urbanski MJ & Szabo B (2006). Analysis of the effects of cannabinoids on identified synaptic connections in the caudate-putamen by paired recordings in transgenic mice. J Physiol 575, 789-806.
30. Freund TF, Katona I & Piomelli D (2003). Role of endogenous cannabinoids in synaptic signaling. Physiol Rev 83, 1017-1066.
31. Galante M & Diana MA (2004). Group I metabotropic glutamate receptors inhibit GABA release at interneuron -Purkinje cell synapses through endocannabinoid production. J Neurosci 24, 4865-4874.
32. Gerdeman GL & Lovinger DM (2003). Emerging roles for endocannabinoids in long-term synaptic plasticity. Br J Pharmacol 140, 781-789.
33. Gerdeman GL, Ronesi J & Lovinger DM (2002). Postsynaptic endocannabinoid release is critical to long-term depression in the striatum. Nat Neurosci 5, 446-451.
34. Gulyas AI, Cravatt BF, Bracey MH, Dinh TP, Piomelli D, Boscia F & Freund TF (2004). Segregation of two endocannabinoid-hydrolyzing enzymes into pre- and postsynaptic compartments in the rat hippocampus, cerebellum and amygdala. Eur J Neurosci 20, 441-458.
35. Hait WN, Glazer L, Kaiser C, Cross J & Kennedy KA (1987). Pharmacological properties of fluphenazine-mustard, an irreversible calmodulin antagonist. Mol Pharmacol 32, 404-409.
36. 2+ dependency for triggering retrograde endocannabinoid signal. Neuron 45, 257-268.
37. Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA, Felder CC, Herkenham M, Mackie K, Martin BR, Mechoulam R & Pertwee RG (2002). International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 54, 161-202.
38. Ishida A & Fujisawa H (1995). Stabilization of calmodulin-dependent protein kinase II through the autoinhibitory domain. J Biol Chem 270, 2163-2170.
39. Jung K-M, Mangieri R, Stapleton C, Kim J, Fegley D, Wallace M, Mackie K & Piomelli D (2005). Stimulation of endocannabinoid formation in brain slice cultures through activation of group I metabotropic glutamate receptors. Mol Pharmacol 68, 1196-1202.
40. 2+/calmodulin-dependent kinase II. Proc Natl Acad Sci U S A 93, 13351-13356.
41. Kathuria S, Gaetani S, Fegley D, Valino F, Duranti A, Tontini A et al. (2003). Modulation of anxiety through blockade of anandamide hydrolysis. Nat Med 9, 76-81.
42. Kawamura Y, Fukaya M, Maejima T, Yoshida T, Miura E, Watanabe M, Ohno-Shosaku T & Kano M (2006). The CB1 cannabinoid receptor is the major cannabinoid receptor at excitatory presynaptic sites in the hippocampus and cerebellum. J Neurosci 26, 2991-3001.
43. Kim J & Alger BE (2004). Inhibition of cyclooxygenase-2 potentiates retrograde endocannabinoid effects in hippocampus. Nat Neurosci 7, 697-698.
44. Kim J, Isokawa M, Ledent C & Alger BE (2002). Activation of muscarinic acetylcholine receptors enhances the release of endogenous cannabinoids in the hippocampus. J Neurosci 22, 10182-10191.
45. Kozak KR, Rowlinson SW & Marnett LJ (2000). Oxygenation of the endocannabinoid, 2-arachidonoylglycerol, to glyceryl prostaglandins by cyclooxygenase-2. J Biol Chem 275, 33744-33749.
46. Kreitzer AC, Carter AG & Regehr WG (2002). Inhibition of interneuron firing extends the spread of endocannabinoid signaling in the cerebellum. Neuron 34, 787-796.
47. Kreitzer AC & Regehr WG (2001). Retrograde inhibition of presynaptic calcium influx by endogenous cannabinoids at excitatory synapses onto Purkinje cells. Neuron 29, 717-727.
48. Lichtman AH, Hawkins GE, Griffin G & Cravatt BF (2002). Pharmacological activity of fatty acid amides is regulated, but not mediated, by fatty acid amide hydrolase in vivo. J Pharmacol Exp Ther 302, 73-79.
49. Llano I, Leresche N & Marty A (1991). Calcium entry increases the sensitivity of cerebellar Purkinje cells to applied GABA and decreases inhibitory synaptic currents. J Neurosci 6, 565-574.
50. Maejima T, Hashimoto K, Yoshida T, Aiba A & Kano M (2001). Presynaptic inhibition caused by retrograde signal from metabotropic glutamate to cannabinoid receptors. Neuron 31, 463-475.
51. 2+ -assisted metabotropic glutamate receptor subtype 1 to phospholipase C β4 signaling cascade in the cerebellum. J Neurosci 25, 6826-6835.
52. Maione S, Bisogno T, de Novellis V, Palazzo E, Cristino L, Valenti M, Petrosino S, Guglielmotti V, Rossi F & Di Marzo V (2006). Elevation of endocannabinoid levels in the ventrolateral periaqueductal grey through inhibition of fatty acid amide hydrolase affects descending nociceptive pathways via both cannabinoid receptor type 1 and transient receptor potential vanilloid type-1 receptors. J Pharmacol Exp Ther 316, 969-982.
53. Makara JK, Mor M, Fegley D, Szabo SI, Kathuria S, Astarita G, Duranti A, Tontini A, Tarzia G, Rivara S, Freund TF & Piomelli D (2005). Selective inhibition of 2-AG hydrolysis enhances endocannabinoid signaling in hippocampus. Nat Neurosci 8, 1139-1141.
54. Marcaggi P & Attwell D (2005). Endocannabinoid signaling depends on the spatial pattern of synapse activation. Nat Neurosci 8, 776-781.
55. Mechoulam R, Ben-Shabat S, Hanus L, Ligumsky M, Kaminski NE, Schatz AR et al. (1995). Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 50, 83-90.
56. Mechoulam R, Fride E & Di Marzo V (1998). Endocannabinoids. Eur J Pharmacol 359, 1-18.
57. Melis M, Perra S, Muntoni AL, Pillolla G, Lutz B, Marsicano G, Di Marzo V, Gessa GL & Pistis M (2004). Prefrontal cortex stimulation induces 2-arachidonoyl-glycerol-mediated suppression of excitation in dopamine neurons. J Neurosci 24, 10707-10715.
58. Moriyama T, Urade R & Kito M (1999). Purification and characterization of diacylglycerol lipase from human platelets. J Biochem 125, 1077-1085.
59. Ohno-Shosaku T, Maejima T & Kano M (2001). Endogenous cannabinoids mediate signals from depolarized postsynaptic neurons to presynaptic terminals. Neuron 29, 729-738.
60. Ohno-Shosaku T, Tsubokawa H, Mizushima I, Yoneda N, Zimmer A & Kano M (2002). Presynaptic cannabinoid sensitivity is a major determinant of depolarization-induced retrograde suppression at hippocampal synapses. J Neurosci 22, 3864-3872.
61. Okamoto Y, Morishita J, Tsuboi K, Tonai T & Ueda N (2004). Molecular characterization of a phospholipase D generating anandamide and its congeners. J Biol Chem 279, 5298-5305.
62. Penning TD, Talley JJ, Bertenshaw SR, Carter JS, Collins PW, Docter S et al. (1997). Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: Identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl) -1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib). J Med Chem 40, 1347-1365.
63. Pertwee RG (2005). Pharmacological actions of cannabinoids. In Cannabinoids, Handbook of Experimental Pharmacology, ed. Pertwee RG, vol. 168, pp. 1-51. Springer-Verlag, Heidelberg.
64. Piomelli D (2003). The molecular logic of endocannabinoid signalling. Nat Rev Neurosci 4, 873-884.
65. Rezazadeh S, Claydon T & Fedida D (2006). KN-93 (2-[N -(2-hydroxyethyl)]- N -(4-methoxybenzenesulfonyl)]-amino- N -(4-chlorocinnamyl)- N -methylbenzylamine), a calcium/ calmodulin-dependent protein kinase II inhibitor, is a direct extracellular blocker of voltage-gated potassium channels. J Pharmacol Exp Ther 317, 292-299.
66. Robbe D, Kopf M, Remaury A, Bockaert J & Manzoni OJ (2002). Endogenous cannabinoids mediate long-term synaptic depression in the nucleus accumbens. Proc Natl Acad Sci U S A 99, 8384-8388.
67. Saario SM, Savinainen JR, Laitinen JT, Järvinen T & Niemi R (2004). Monoglyceride lipase-like enzymatic activity is responsible for hydrolysis of 2-arachidonoylglycerol in rat cerebellar membranes. Biochem Pharmacol 67, 1381-1387.
68. Safo PK & Regehr WG (2005). Endocannabinoids control the induction of cerebellar LTD. Neuron 48, 647-659.
69. Stella N, Schweitzer P & Piomelli D (1997). A second endogenous cannabinoid that modulates long-term potentiation. Nature 388, 773-778.
70. Straiker A & Mackie K (2005). Depolarization-induced suppression of excitation in murine autaptic hippocampal neurones. J Physiol 569, 501-517.
71. Sugiura T, Kobayashi Y, Oka S & Waku K (2002). Biosynthesis and degradation of anandamide and 2-arachidonoylglycerol and their possible physiological significance. Prostaglandins Leukot Essent Fatty Acids 66, 173-192.
72. Sugiura T, Kondo S, Sukagawa A, Nakane S, Shinoda A, Itoh K, Yamashita A & Waku K (1995). 2-Arachidonoylglycerol: A possible endogenous cannabinoid receptor ligand in the brain. Biochem Biophys Res Commun 215, 89-97.
73. Szabo B & Schlicker E (2005). Effects of cannabinoids on neurotransmission. In Cannabinoids, Handbook of Experimental Pharmacology, ed. Pertwee RG, vol. 168, pp 372-365. Springer-Verlag, Heidelberg.
74. Szabo B, Than M, Thorn D & Wallmichrath I (2004). Analysis of the effects of cannabinoids on synaptic transmission between basket and Purkinje cells in the cerebellar cortex of the rat. J Pharmacol Exp Ther 310, 915-925.
75. Szabo B, Urbanski MJ & Di Marzo V (2005). The role of 2-arachidonylglycerol in retrograde signaling. 2005 Symposium on the Cannabinoids, International Cannabinoid Research Society, Burlington, Vermont, S14.
76. Takahashi KA & Linden DJ (2000). Cannabinoid receptor modulation of synapses received by cerebellar Purkinje cells. J Neurophysiol 83, 1167-1180.
77. 2+/calmodulin-dependent protein kinase II activity in living neurons. J Neurosci 25, 3107-3112.
78. Urbanski MJ, Mendiguren A, Urbani P, Di Marzo V & Szabo B (2005). Depolarisation-induced suppression of inhibition is mediated by 2-arachidonoylglycerol. Naunyn Schmiedebergs Arch Pharmacol 371, R72.
79. Varma N, Carlson GC, Ledent C & Alger BE (2001). Metabotropic glutamate receptors drive the endocannabinoid system in hippocampus. J Neurosci 21, RC188.
80. Wallmichrath I & Szabo B (2002). Cannabinoids inhibit striatonigral GABAergic neurotransmission in the mouse. Neuroscience 113, 671-682.
81. Wilson RI & Nicoll RA (2001). Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses. Nature 410, 588-592.
82. Wilson RI & Nicoll RA (2002). Endocannabinoid signaling in the brain. Science 296, 678-682.
83. Xia Z & Storm DR (2005). The role of calmodulin as a signal integrator for synaptic plasticity. Nat Rev Neurosci 6, 267-276.
84. Yoshida T, Fukaya M, Uchigashima M, Miura E, Kamiya H, Kano M & Watanabe M (2006). Localization of diacylglycerol lipase-α around postsynaptic spine suggests close proximity between production site of an endocannabinoid, 2-arachidonoyl-glycerol, and presynaptic cannabinoid CB1 receptor. J Neurosci 26, 4740-4751.